Boerner S - Search Results

1

Challenges with Novel Clinical Trial Designs: Master Protocols.

Cecchini M, Rubin EH, Blumenthal GM, Ayalew K, Burris HA, Russell-Einhorn M, Dillon H, Lyerly HK, Reaman GH, Boerner S, LoRusso PM. Cecchini M, et al. Among authors: boerner s. Clin Cancer Res. 2019 Apr 1;25(7):2049-2057. doi: 10.1158/1078-0432.CCR-18-3544. Epub 2019 Jan 29. Clin Cancer Res. 2019. PMID: 30696689

2

Clinical experience of MEK inhibitors in cancer therapy.

Wang D, Boerner SA, Winkler JD, LoRusso PM. Wang D, et al. Biochim Biophys Acta. 2007 Aug;1773(8):1248-55. doi: 10.1016/j.bbamcr.2006.11.009. Epub 2006 Nov 16. Biochim Biophys Acta. 2007. PMID: 17194493 Free article. Review.

3

Non-rash skin toxicities associated with novel targeted therapies.

Lacouture ME, Boerner SA, Lorusso PM. Lacouture ME, et al. Clin Lung Cancer. 2006 Dec;8 Suppl 1:S36-42. doi: 10.3816/clc.2006.s.012. Clin Lung Cancer. 2006. PMID: 17239289 Review.

4

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.

LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, DeLuca PA, Evelhoch JL, Boerner SA, Wheeler C. LoRusso PM, et al. Among authors: boerner sa. Invest New Drugs. 2008 Apr;26(2):159-67. doi: 10.1007/s10637-008-9112-9. Epub 2008 Jan 25. Invest New Drugs. 2008. PMID: 18219445 Clinical Trial.

5

Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies.

Goncalves PH, High F, Juniewicz P, Shackleton G, Li J, Boerner S, LoRusso PM. Goncalves PH, et al. Among authors: boerner s. Invest New Drugs. 2008 Aug;26(4):347-54. doi: 10.1007/s10637-008-9135-2. Epub 2008 May 1. Invest New Drugs. 2008. PMID: 18449472 Free PMC article. Clinical Trial.

6

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Eder JP, et al. Clin Cancer Res. 2009 Apr 1;15(7):2207-14. doi: 10.1158/1078-0432.CCR-08-1306. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318488 Review.

7

A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.

Burris HA 3rd, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L, Ho PT, Boerner SA, Lorusso P. Burris HA 3rd, et al. Invest New Drugs. 2011 Jun;29(3):467-72. doi: 10.1007/s10637-009-9374-x. Epub 2010 Jan 13. Invest New Drugs. 2011. PMID: 20069338 Clinical Trial.

8

An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.

LoRusso PM, Boerner SA, Seymour L. LoRusso PM, et al. Clin Cancer Res. 2010 Mar 15;16(6):1710-8. doi: 10.1158/1078-0432.CCR-09-1993. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215546 Review.

9

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM. Eder JP, et al. Among authors: boerner sa. Clin Cancer Res. 2010 Jul 1;16(13):3507-16. doi: 10.1158/1078-0432.CCR-10-0574. Epub 2010 May 14. Clin Cancer Res. 2010. PMID: 20472683 Clinical Trial.

10

The role of phosphoinositide 3-kinase in breast cancer: an overview.

LoRusso PM, Boerner SA. LoRusso PM, et al. Clin Breast Cancer. 2010 Nov;10 Suppl 3:S56-8. doi: 10.3816/CBC.2010.s.012. Clin Breast Cancer. 2010. PMID: 21115422 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters